The IGF1R Knockout 769-P Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the 769-P human renal cell carcinoma line, engineered for loss-of-function studies of the insulin-like growth factor 1 receptor (IGF1R). By introducing targeted disruptions in the IGF1R gene, this heterogeneous knockout pool provides a physiologically relevant model for investigating IGF1R-dependent signaling pathways, without the need for single-cell clonal isolation. The polyclonal format captures a broad spectrum of genetic edits, offering a robust and scalable system for high-throughput screening, signaling analyses, and functional genomics in a cancer-relevant background.
The parental 769-P cell line originates from a clear cell renal cell carcinoma (ccRCC), a common and aggressive kidney cancer characterized by dysregulated hypoxia-inducible factor and metabolic reprogramming. As a cancerous epithelial line, 769-P cells retain hallmark features of ccRCC, including activation of multiple receptor tyrosine kinase pathways that drive unchecked proliferation, survival, and metabolic plasticity. This genetic backdrop makes 769-P a well-suited host for interrogating oncogenic signaling circuits, particularly those involving growth factor receptors such as IGF1R, which are frequently overexpressed or hyperactivated in renal malignancies and contribute to tumor progression and therapeutic resistance.
IGF1R encodes a receptor tyrosine kinase that serves as a central node in growth factor signaling, activated by its ligands IGF1, IGF2, and insulin, and regulated upstream by transcription factors such as STAT5B and SP1. Upon ligand engagement, IGF1R autophosphorylates and recruits key adaptor proteins IRS1 and SHC, which in turn promote assembly of signaling complexes containing GRB2, SOS, and PI3K. These interactions bifurcate signaling through the PI3K?CAKT?CmTOR axis, driving metabolic and survival programs, and the RAS?CRAF?CMEK?CERK cascade, which governs proliferation. Downstream effectors include AKT, mTOR, ERK1/2, and S6K, while phosphatases like PTPN11 modulate signal duration. Thus, IGF1R coordinates a complex signaling network that integrates nutrient and growth cues to regulate cell fate.
In the context of 769-P ccRCC cells, IGF1R knockout models are invaluable for dissecting the receptor??s contribution to malignant phenotypes. Aberrant IGF1R signaling is implicated in renal cell carcinoma progression, metastasis, and resistance to targeted therapies, partly through crosstalk with the PI3K-AKT and MAPK/ERK pathways. Disruption of IGF1R in these cells is anticipated to impair downstream phosphorylation of AKT and ERK, attenuate mTOR-driven protein synthesis, and reduce S6K activation, thereby suppressing tumor cell growth, survival, and invasive capacity. This polyclonal knockout population enables researchers to assess the collective impact of IGF1R loss on cellular processes without the biases of single clones, faithfully reflecting the heterogeneity of cancer cell populations.
Typical research applications include mechanistic studies of IGF1R signaling in renal cell carcinoma, functional genomics screens, and investigations of drug resistance. This knockout product is suitable for western blotting to assess phospho-IGF1R, phospho-AKT, and phospho-ERK levels, RT-qPCR profiling of downstream target gene expression, cell proliferation assays (e.g., MTS/MTT), apoptosis detection via Annexin V staining, and migration or invasion assays. By providing a ready-to-use polyclonal knockout system, researchers can accelerate pathway analysis, validate therapeutic targets, and explore the role of IGF1R in cancer cell biology. For further information, please contact Ascent Research.
